Cutting Edge Data Reveals Improved Sensitivity of PD Motor Progression with Wearable Sensors Webinar Replay
The development and deployment of disease-modifying interventions for Parkinson’s disease (PD) have been limited due to a lack of objective, accurate and reliable measures of progression. As such, the adoption of digital technologies has increased in recent years with the intent to overcome the poor sensitivity of conventional rating scales currently used as the gold standard in clinical trials. However, natural history studies incorporating digital motor endpoints in PD are sparse. Excitingly, data recently published from key longitudinal studies reveal cutting-edge evidence demonstrating that digital endpoints of motor progression are more sensitive than conventional clinical scales.
Join Clario, along with their guest speakers, as they discuss the latest research and clinical developments in which wearable sensor detection of progression is impacting the field of Parkinson’s research. The featured speakers will present data from longitudinal progression investigations including the Oxford Quantification in Parkinsonism (OxQUIP) study, the Wearable Assessments in the Clinic and Home in Parkinson’s Disease (WATCH-PD) study and more.
What you’ll learn:
- How digital endpoints of gait and balance in PD, combined with machine learning, provide more sensitivity to disease progression than the movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS) Part III (or traditional endpoints)
- By capturing a composite score of digital measures of bradykinesia with wearable sensors, a better signal of disease progression can be provided compared to independent measurements
- Future directions of wearable sensor and digital motor endpoints in clinical trials to monitor the progression of neurodegenerative disease
